A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma.
Latest Information Update: 05 Aug 2020
Price :
$35 *
At a glance
- Drugs Sunitinib (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2018 Status changed from active, no longer recruiting to completed.
- 26 Apr 2018 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Planned End Date changed from 1 Jul 2017 to 31 Jan 2019.